Glypican-3 (GPC3) represents an attractive target for hepatocellular carcinoma (HCC) therapy because it is highly expressed in HCC but not in adult normal tissue. Recently, high affinity anti-GPC3 ...

Purple Biotech showcased its CAPTN-3 tri-specific antibody platform's preclinical data at EACR 2025, demonstrating significant anti-tumor activity.